当前位置： SCI文献检索 > ANNALS OF INTERNAL MEDICINE期刊下所有文献 > Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial.

Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial.

Abstract：

OBJECTIVE:To determine whether oral acyclovir reduces the incidence of recurrent herpes labialis in otherwise healthy patients with proven frequently recurrent disease. DESIGN:Randomized, double-blind, placebo-controlled, crossover trial. SETTING:Outpatient facility of the Clinical Center, National Institutes of Health, Bethesda, Maryland. PATIENTS:Fifty-six otherwise healthy adults who reported frequently recurrent herpes labialis (> or = 6 episodes/y) were enrolled into the study. During a 4-month observation period, 22 patients had herpes labialis two or more times and were eligible for study treatment. INTERVENTIONS:Twenty-two patients were randomized to receive either acyclovir, 400 mg twice daily, or matched placebo for 4 months. After the first treatment period, patients were given the alternate treatment for another 4 months and were then taken off study medication to observe the first post-treatment recurrence. Recurrent outbreaks were determined by examination and by viral culture. RESULTS:Twenty patients completed blind treatment with both acyclovir and placebo. The median time to first clinically documented recurrence was 46 days for placebo courses and 118 days for acyclovir courses (P = 0.05). The mean number of recurrences per 4-month treatment period was 1.80 episodes per patient during placebo treatment and 0.85 episodes per patient during acyclovir treatment (P = 0.009). The mean number of virologically confirmed recurrences per patient was 1.40 with placebo therapy compared with 0.40 with acyclovir (P = 0.003). CONCLUSIONS:Oral acyclovir, 400 mg twice daily, is effective in suppressing herpes labialis in immunocompetent adults confirmed to have frequently recurrent infection. Treatment with acyclovir in this study resulted in a 53% reduction in the number of clinical recurrences and a 71% reduction in virus culture-positive recurrences compared with placebo therapy.

journal_name

Ann Intern Med

journal_title

Annals of internal medicine

authors

Rooney JF,Straus SE,Mannix ML,Wohlenberg CR,Alling DW,Dumois JA,Notkins AL

doi

10.7326/0003-4819-118-4-199302150-00004

subject

Has Abstract

pub_date

1993-02-15 00:00:00

pages

268-72

issue

eissn

0003-4819

issn

1539-3704

journal_volume

118

pub_type

临床试验,杂志文章,随机对照试验

在线工具

Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial.